ID   GLC-4/ADR
AC   CVCL_4997
SY   GLC4-Adr; GLC4/ADR; GLC(4)/ADR; GLC4/ADR350x; GLC4-ADR150; GLC4-Adr1
DR   BTO; BTO_0002386
DR   ChEMBL-Cells; CHEMBL3833703
DR   PubChem_Cell_line; CVCL_4997
DR   Wikidata; Q54835913
RX   PubMed=1657425;
RX   PubMed=3028613;
RX   PubMed=3040227;
RX   PubMed=7729950;
RX   PubMed=7809167;
RX   PubMed=8980384;
RX   PubMed=11309308;
CC   Doubling time: 26 hours (PubMed=3028613).
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0279 ! GLC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 18
//
RX   PubMed=1657425; DOI=10.1007/BF00685823;
RA   de Jong S., Zijlstra J.G., Mulder N.H., de Vries E.G.E.;
RT   "Lack of cross-resistance to fostriecin in a human small-cell lung
RT   carcinoma cell line showing topoisomerase II-related drug resistance.";
RL   Cancer Chemother. Pharmacol. 28:461-464(1991).
//
RX   PubMed=3028613;
RA   Zijlstra J.G., de Vries E.G.E., Mulder N.H.;
RT   "Multifactorial drug resistance in an adriamycin-resistant human small
RT   cell lung carcinoma cell line.";
RL   Cancer Res. 47:1780-1784(1987).
//
RX   PubMed=3040227;
RA   Meijer C., Mulder N.H., Timmer-Bosscha H., Zijlstra J.G.,
RA   de Vries E.G.E.;
RT   "Role of free radicals in an adriamycin-resistant human small cell
RT   lung cancer cell line.";
RL   Cancer Res. 47:4613-4617(1987).
//
RX   PubMed=7729950; DOI=10.1002/ijc.2910610317;
RA   Versantvoort C.H.M., Withoff S., Broxterman H.J., Kuiper C.M.,
RA   Scheper R.J., Mulder N.H., de Vries E.G.E.;
RT   "Resistance-associated factors in human small-cell lung-carcinoma GLC4
RT   sub-lines with increasing adriamycin resistance.";
RL   Int. J. Cancer 61:375-380(1995).
//
RX   PubMed=7809167; DOI=10.1073/pnas.91.26.13033; PMCID=PMC45575;
RA   Muller M., Meijer C., Zaman G.J.R., Borst P., Scheper R.J., Mulder N.H.,
RA   de Vries E.G.E., Jansen P.L.M.;
RT   "Overexpression of the gene encoding the multidrug
RT   resistance-associated protein results in increased ATP-dependent
RT   glutathione S-conjugate transport.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:13033-13037(1994).
//
RX   PubMed=8980384; DOI=10.1038/bjc.1996.647; PMCID=PMC2074800;
RA   Withoff S., de Vries E.G.E., Keith W.N., Nienhuis E.F.,
RA   van der Graaf W.T.A., Uges D.R.A., Mulder N.H.;
RT   "Differential expression of DNA topoisomerase II alpha and -beta in
RT   P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines
RT   of the human SCLC cell line GLC4.";
RL   Br. J. Cancer 74:1869-1876(1996).
//
RX   PubMed=11309308;
RA   Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A.,
RA   Pijnenborg A.C.L.M., Schinkel A.H., van de Vijver M.J., Scheper R.J.,
RA   Schellens J.H.M.;
RT   "Subcellular localization and distribution of the breast cancer
RT   resistance protein transporter in normal human tissues.";
RL   Cancer Res. 61:3458-3464(2001).
//